BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 2529150)

  • 1. Steroid-induced dermal atrophy. Investigations on discontinuous application.
    Lubach D; Bensmann A; Bornemann U
    Dermatologica; 1989; 179(2):67-72. PubMed ID: 2529150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development and regression of dermal corticosteroid atrophy. 1. Change in the skinfold thickness].
    Lubach D; Hinz E
    Derm Beruf Umwelt; 1986; 34(5):146-9. PubMed ID: 2947794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development and regression of dermal corticosteroid atrophy. 3. Results of discontinuous topical corticosteroid administration].
    Bensmann A; Lubach D
    Derm Beruf Umwelt; 1987; 35(1):20-3. PubMed ID: 2952481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Domoprednate (Stermonid), a topical D-homocorticosteroid, skin atrophy and telangiectasia. A double-blind, randomized comparison with hydrocortisone butyrate, betamethasone valerate, clobetasole propionate and placebo.
    Serup J; Holm P
    Dermatologica; 1985; 170(4):189-94. PubMed ID: 3888708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous mast cell depletion results from topical corticosteroid usage.
    Lavker RM; Schechter NM
    J Immunol; 1985 Oct; 135(4):2368-73. PubMed ID: 4031494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The hairless mouse as a model for study of local and systemic atrophogenic effects following topical application of corticosteroids.
    van den Hoven WE; van den Berg TP; Korstanje C
    Acta Derm Venereol; 1991; 71(1):29-31. PubMed ID: 1676210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development and regression of dermal corticosteroid atrophy. 2. Changes in compression rate].
    Hinz E; Lubach D
    Derm Beruf Umwelt; 1986; 34(6):174-8. PubMed ID: 3816581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of local corticosteroids on acute experimental urticaria.
    Nancey S; Freymond N; Catelain A; Cousin F; Rozieres A; Nicolas JF
    Eur J Dermatol; 2004; 14(5):323-6. PubMed ID: 15358571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinico-experimental testing for anti-inflammatory activity of external corticosteroids].
    Böttger E; Koch E; Tronnier H
    Berufsdermatosen; 1977 Apr; 25(2):53-62. PubMed ID: 869888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Optimized interval treatment of eczema with fluprednidene. A multicenter double-blind study].
    Mahrle G; Wemmer U; Matthies C
    Z Hautkr; 1989 Sep; 64(9):766-8, 773-4. PubMed ID: 2683439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of atrophy of human skin caused by corticosteroids using chamber occlusion and suction blister techniques.
    Somerma S; Lassus A; Salde L
    Acta Derm Venereol; 1984; 64(1):41-5. PubMed ID: 6203280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicology and Carcinogenesis Studies of 4-Vinyl-1-cyclohexene Diepoxide (CAS No. 106-87-6) in F344/N Rats and B6C3F1 Mice (Dermal Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1989 Nov; 362():1-249. PubMed ID: 12695779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of urticaria pigmentosa with corticosteroids.
    Barton J; Lavker RM; Schechter NM; Lazarus GS
    Arch Dermatol; 1985 Dec; 121(12):1516-23. PubMed ID: 4062333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of topical corticosteroid activity using the vasoconstriction assay in healthy volunteers.
    Görne RC; Greif C; Metzner U; Wigger-Alberti W; Elsner P
    Skin Pharmacol Physiol; 2007; 20(3):133-40. PubMed ID: 17191036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methods for the assessment of skin atrophogenicity of topical corticosteroids.
    Marks R
    Dermatologica; 1976; 152 Suppl 1():117-26. PubMed ID: 133834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent application of tretinoin (retinoic acid) partially protects against corticosteroid-induced epidermal atrophy.
    McMichael AJ; Griffiths CE; Talwar HS; Finkel LJ; Rafal ES; Hamilton TA; Voorhees JJ
    Br J Dermatol; 1996 Jul; 135(1):60-4. PubMed ID: 8776360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of contact hypersensitivity to corticosteroids in allergic contact dermatitis patients who do not respond to topical corticosteroids.
    Gönül M; Gül U
    Contact Dermatitis; 2005 Aug; 53(2):67-70. PubMed ID: 16033397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Steroid atrophy--a histological appraisal.
    Jones EW
    Dermatologica; 1976; 152 Suppl 1():107-15. PubMed ID: 133833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multitechnique evaluation of topical corticosteroid treatment.
    Josse G; Rouvrais C; Mas A; Haftek M; Delalleau A; Ferraq Y; Ossant F; George J; Lagarde JM; Schmitt AM
    Skin Res Technol; 2009 Feb; 15(1):35-9. PubMed ID: 19152576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contact allergy to topical corticosteroids--results from the IVDK and epidemiological risk assessment.
    Uter W; de Pádua CM; Pfahlberg A; Nink K; Schnuch A; Lessmann H
    J Dtsch Dermatol Ges; 2009 Jan; 7(1):34-41, 34-42. PubMed ID: 18761609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.